Please assess the completion status of the following clinical trial:

Trial Title: L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults ages 18-55 years of age~* A diagnosis of childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD), meeting the Diagnostic and Statistical Manual, Fifth Edition (DSM-V) criteria for ADHD in adulthood, including at least 5 current symptoms of inattentive or impulsive-hyperactive traits, and childhood onset by age 12, defined as two symptoms of inattentive or of impulsive/hyperactive traits by the age of 12~* A score of 20 or more on the Adult ADHD Investigator Symptom Report Scale (AISRS), and, for those individuals stably treated with stimulants, a Clinical Global Impression -ADHD (CGI-ADHD) severity score of no greater than 4 (moderately ill)~* Subjects on a stable dose of stimulant medication must be treated on the same dose for at least 1 month prior to study entry~Exclusion Criteria:~* A history of intolerance to magnesium supplementation, or the ingredients in MMFS202 (6-hour release) AND MMFS302 (12-hour release)~* Pregnant or nursing females~* A known unstable medical illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including hypertension ≥ 140/90 mmHg at screening), endocrinologic (e.g. thyroid), neurologic (e.g. seizure), immunologic, hematologic, or psychiatric (other than ADHD) disorder); individuals with kidney dysfunction will be excluded, as dysfunctional kidneys may have difficulty clearing the magnesium from the body (which can result in dangerously high magnesium levels); individuals with heart block will be excluded from the study~* Any medical condition that the Principal Investigator (PI) believes will be exacerbated by study participation~* A history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to screening~* A known history of narrow-angle glaucoma~* Current (within 3 months) DSM-V criteria for abuse or dependence with any psychoactive substance other than nicotine~* Intelligence Quotient (IQ) less than 80 (based on the Wechsler Abbreviated Scale of Intelligence-II Full Scale IQ calculation)~* Multiple adverse drug reactions~* Any other concomitant medication with primarily central nervous system activity as specified in the study protocol~* Current use of a monoamine-oxidase inhibitor (MAOI) or use within the past two weeks~* Current use of antibiotics, as the study agent may reduce the absorption of antibiotics~* Subjects may not take any of the following substances for at least 7 days prior to baseline and throughout the study: Calcium channel blockers; any psychoactive medications; any medications known to interact with magnesium; supplemental magnesium or any magnesium-containing products; all dietary or herbal supplements or products including those purported to improve memory, improve sleep, or decrease stress.~* Investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent, or grandchild

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- L-Threonic Acid Magnesium Salt (L-TAMS) (Type: EXPERIMENTAL): Subjects received open label L-Threonic acid Magnesium salt for 12 weeks. Subjects took MMFS202 (6-hour release) and MMFS302 (12-hour release) by mouth each day, up to three times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).